October 11, 2016 / 5:46 AM / a year ago

BRIEF-NanoCarrier affirms safety profile and efficacy of NC-6004 in Phase Ib clinical study in US

Oct 11 (Reuters) - NanoCarrier Co Ltd :

* Says it confirmed safety profile and efficacy of NC-6004 in the Phase Ib clinical study conducted in the U.S.

Source text in Japanese:goo.gl/XsXi3w

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below